Abiraman

Absinta

Achyuta

Ackerman

Agarwal

Agoston

Almeida

Atay

Balakin

Baraban

Barnett

Bartheld

Bartzokis

Bechler

Bercury

Berdichevsky

Bieber

Bielen

Biffi

Birgbauer

Blakemore

Bodini

Boespflug-Tanguy

Boyd

Brenner

Brown

Buckley

Bujalka

Bunge

Buser

Chang

Chen

Chong

Choucha Snouber

Chung

Comi

Compston

Correale

Craner

Crofton

Cusick

Czopka

Dale

Dawson

Deshmukh

Dombrowski

Domingues

Eiraku

Ellett

Emery

Esch

Fancy

Ferent

Fields

Filley

Franklin

Freeman

Friedman

Frühbeis

Fujita-Jimbo

Fyffe-Maricich

Fünfschilling

Gaesser

Galloway

Garden

Garver

Gibson

Gilmour

Gledhill

Goebbels

Gogolla

Goldschmidt

Gonsalvez

Gritsch

Grossman

Haber

Hammond

Heck

Hercher

Hickey

Hines

Howe

Huang

Hughes

Katy L. H. Cole

Jason J. Early

David A. Lyons

Crossref

Glia

Drug discovery for remyelination and treatment of MS

Glia constitute the majority of the cells in our nervous system, yet there are currently no drugs that target glia for the treatment of disease. Given ongoing discoveries of the many roles of glia in numerous diseases of the nervous system, this is likely to change in years to come. Here we focus on the possibility that targeting the oligodendrocyte lineage to promote regeneration of myelin (remyelination) represents a therapeutic strategy for the treatment of the demyelinating disease multiple sclerosis, MS. We discuss how hypothesis driven studies have identified multiple targets and pathways that can be manipulated to promote remyelination in vivo, and how this work has led to the first ever remyelination clinical trials. We also highlight how recent chemical discovery screens have identified a host of small molecule compounds that promote oligodendrocyte differentiation in vitro. Some of these compounds have also been shown to promote myelin regeneration in vivo, with one already being trialled in humans. Promoting oligodendrocyte differentiation and remyelination represents just one potential strategy for the treatment of MS. The pathology of MS is complex, and its complete amelioration may require targeting multiple biological processes in parallel. Therefore, we present an overview of new technologies and models for phenotypic analyses and screening that can be exploited to study complex cell-cell interactions in in vitro and in vivo systems. Such technological platforms will provide insight into fundamental mechanisms and increase capacities for drug-discovery of relevance to glia and currently intractable disorders of the CNS.</p

Drug discovery for remyelination and treatment of MS

Abstract

Similar works

Full text

Available Versions

Crossref

Edinburgh Research Explorer